GT BIOPHARMA, INC. Payments of Stock Issuance Costs
GT BIOPHARMA, INC. (GTBP) reported Payments of Stock Issuance Costs of $1.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-14
- GT BIOPHARMA, INC. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00.
- GT BIOPHARMA, INC. payments of stock issuance costs for the quarter ending 2026-03-31 was $1.10M, a 0.00% change year-over-year.
- GT BIOPHARMA, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- GT BIOPHARMA, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00.
- GT BIOPHARMA, INC. payments of stock issuance costs for fiscal 2025 was $1.10M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.10M 10-Q · filed 2026-08-14 | $1.10M derived: sum of 3 quarters · filed 2026-08-14 | $1.10M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-15 | $1.10M derived: sum of 2 quarters · filed 2026-05-15 | $1.10M derived: sum of 3 quarters · filed 2026-05-15 | $1.10M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | $0.00 derived: sum of 3 quarters · filed 2026-03-06 | $1.10M 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2026-03-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | $1.10M 10-Q/A · filed 2026-03-06 | |
| 2025-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q 3 month · filed 2026-03-06 | $1.10M 10-Q/A · filed 2026-03-06 | ||
| 2025-03-31 | $1.10M 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |